Company profile: Animol Discovery
1.1 - Company Overview
Company description
- Provider of a drug discovery platform combining DNA-encoded chemical libraries, AI/ML, and computational chemistry to rapidly identify novel veterinary medicines; focuses on discovering and developing small-molecule drugs for companion and farm animals addressing infectious and chronic diseases, with a proprietary pipeline of veterinary small molecules including next-generation antiparasitics and therapeutics.
Products and services
- Drug Discovery Platform: Animol’s AI-driven platform integrates DNA-encoded chemical libraries, machine learning, and computational chemistry to rapidly identify novel veterinary medicines and accelerate discovery workflows
- Pipeline of Veterinary Small Molecules: Animol’s proprietary pipeline of veterinary small molecules addresses a range of animal conditions, leveraging the platform for accelerated discovery and development of novel veterinary medicines
- Small Molecule Pharmaceuticals: Animol discovers and develops veterinary-grade small-molecule drugs for veterinary use, addressing infectious and chronic diseases in companion and farm animals.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Animol Discovery
Chiva Pharmaceuticals
HQ: United States
Website
- Description: Provider of global pharmaceutical solutions focused on bringing the best standard of care to the Chinese market and making drugs developed in China available worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chiva Pharmaceuticals company profile →
Innate Pharma
HQ: France
Website
- Description: Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innate Pharma company profile →
Merck
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines and vaccines for various diseases, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merck company profile →
Matrx Pharmaceuticals
HQ: Poland
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Matrx Pharmaceuticals company profile →
CB Fleet
HQ: United States
Website
- Description: Provider of feminine care products for personal hygiene and comfort and over-the-counter (OTC) healthcare products addressing common health concerns, serving as a manufacturer, marketer, and distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CB Fleet company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Animol Discovery
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Animol Discovery
2.2 - Growth funds investing in similar companies to Animol Discovery
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Animol Discovery
4.2 - Public trading comparable groups for Animol Discovery
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →